Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study
Open Access
- 18 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 24 (1), 1-10
- https://doi.org/10.1186/s13054-020-02936-0
Abstract
Diffuse alveolar hemorrhage (DAH) occurs during the course of autoimmune disease and may be life threatening. The objective was to assess characteristics and prognosis factors of DAH who required intensive care unit (ICU) admission in patients with autoimmune diseases. French multicenter retrospective study including patients presenting DAH related to autoimmune diseases requiring ICU admission from 2000 to 2016. One hundred four patients (54% of men) with median age of 56 [32–68] years were included with 79 (76%) systemic vasculitis and 25 (24%) connective tissue disorders. All patients received steroids, and 72 (69%), 12 (11.5%), and 57 (55%) patients had cyclophosphamide, rituximab, and plasma exchanges, respectively. During ICU stay, 52 (50%), 36 (35%), and 55 (53%) patients required mechanical ventilation, vasopressor use, and renal replacement therapy, respectively. Factors associated with mechanical ventilation weaning were age (HR [95%CI] 0.97 [0.96–0.99] per 10 years, p < 0.0001), vasculitis-related DAH (0.52 [0.27–0.98], p = 0.04), and time from dyspnea onset to ICU admission (0.99 [0.99–1] per day, p = 0.03). ICU mortality was 15%. Factors associated with alive status at ICU discharge were chronic cardiac failure (HR [95%CI] 0.37 [0.15–0.94], p = 0.04), antiphospholipid syndrome-related DAH (3.17 [1.89–5.32], p < 0.0001), SAPS II (0.98 [0.97–0.99], p = 0.007), and oxygen flow at ICU admission (0.95 [0.91–0.99] per liter/min, p = 0.04). DAH in autoimmune diseases is a life-threatening complication which requires mechanical ventilation in half of the cases admitted to ICU.Keywords
This publication has 34 references indexed in Scilit:
- Primary Antiphospholipid Syndrome–Associated Diffuse Alveolar HemorrhageArthritis Care & Research, 2014
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals Of The Rheumatic Diseases, 2012
- Renal replacement therapy in prolonged mechanical ventilation patients with renal failure in TaiwanJournal of Critical Care, 2011
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure*Critical Care Medicine, 2008
- Prognostic Factors for Hospital Mortality and ICU Admission in Patients With ANCA-Related Pulmonary VasculitisThe American Journal of the Medical Sciences, 2008
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987